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High Incidence and Prevalence of Drug-Related Movement
Disorders in Young Patients With Psychotic Disorders
Thierry Q. Mentzel, MSc,*† Ritsaert Lieverse, MD, PhD,† Oswald Bloemen, MD, PhD,*†
Wolfgang Viechtbauer, PhD,† Peter N. van Harten, MD, PhD,*† and The Genetic
Risk and Outcome of Psychosis (GROUP) Investigators
Abstract:
Background: Drug-related movement disorders (DRMDs) reduce qual-
ity of life and contribute to medication noncompliance of patients with psy-
chotic disorders. Little is known about the epidemiology of DRMDs in
relatively young patients a few years after onset of psychosis. This is an im-
portant period to study, as the impact of the antipsychotic treatment on the
long-term potentiation of the neural pathways associated with psychotic
disorders and DRMDs is still minimal. This study investigated the preva-
lence, incidence, persistence, and clinical correlates of DRMDs in patients
during their first years after disease onset.
Methods: The Genetic Risk and Outcome of Psychosis study is a longi-
tudinal study of 1120 relatively young patients with nonaffective psychosis
and amean age and illness duration of 27 and 4 years, respectively. The fol-
lowing drug-related movement disorders were assessed at baseline and at
the 3-year follow-up: parkinsonism, akathisia, tardive dyskinesia, and tardive
dystonia. We determined prevalence, incidence, and persistence and investi-
gated clinical correlates at and over the baseline and follow-up assessment.
Results: Patients' mean age and illness duration at baseline were 27.1 and
4.3 years, respectively. In 4 patients, 1 developed a DRMD over the 3-year
study period. Prevalence, incidence, and persistence rates were highest for
parkinsonism (32%, 21%, and 53%) followed by akathisia (9%, 5%, and
17%) and tardive dyskinesia (4%, 3%, and 20%). Significant associations
were found betweenDRMDs and the patients' age, IQ, and psychopathology.
Conclusions: The prevalence, persistence, and incidence of DRMDs in
this samplewere high despite the relatively young age, recent onset of the dis-
order, and treatment primarily with second-generation antipsychotics. These
findings emphasize that screening, diagnosis, and treatment of DRMDs are
still important.
Key Words: extrapyramidal symptoms, movement disorders,
epidemiology
(J Clin Psychopharmacol 2017;37: 231–238)
D rug-related movement disorders (DRMDs) are one of themain drawbacks of antipsychotic treatment as they often re-
duce quality of life1 and can contribute to medication noncompli-
ance.2 Drug-related movement disorders are usually divided in
early- and late-onset disorders. Early-onset disorders such as par-
kinsonism (tremor, rigidity, and bradykinesia) and akathisia de-
velop after a relatively short period of antipsychotic treatment,
whereas late-onset disorders such as tardive dyskinesia and dysto-
nia develop after months, years, or decades of antipsychotic treat-
ment. With the introduction of second-generation antipsychotics
(SGAs), a substantial drop in the incidence of DRMDs was
expected as they have a lower DRMD risk profile than first-
generation antipsychotics (FGAs).3–5
Many studies have reported prevalence rates of DRMDs and
some incidence rates, reporting high rates especially for patients
treated with FGAs.3,4,6–8 Typically, these studies investigated pa-
tients on long-term antipsychotic treatment, often with a history
of both FGA and SGA treatment. In comparison, the incidence
and prevalence rates of DRMDs during the first years of antipsy-
chotic treatment are relatively understudied,5 especially for SGA
treatment. The European First-Episode Schizophrenia Trial (EUFEST)
recently studied a large population over their first years of treat-
ment8,9 (age, 26 ± 6 years; illness duration, <2 years). They re-
ported remarkably high DRMD prevalence rates, as high as
34% for FGAs and 28% for SGAs.8 In contrast, in a somewhat
smaller and younger population (age, 20 ± 2; illness duration,
4 ± 2), Gebhardt et al5 reported much lower prevalence rates of
1.1% to 5.4%, although subclinical signs of DRMDs were found
in 39.8% of their study population. Therefore, further research is
warranted, as in addition to these conflicting results, neither of
these studies investigated DRMD incidence and persistence rates.
The Genetic Risk and Outcome of Psychosis (GROUP) study
is a prospective study following a naturalistic design that investi-
gated a large, relatively young (age, 27 ± 7 years; illness duration,
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4 ± 4 years) cohort during 3 years of antipsychotic treatment on a
wide range of clinical outcomes including DRMDs. Therefore, this
sample is ideal for studying the incidence, prevalence, and persis-
tence rates of DRMDs relatively early in the onset of the psychotic
disorder with limited confounding by prior treatment.10 We hy-
pothesized that the prevalence rates of DRMDs in the GROUP
study would lie between the low rates reported by Gebhardt et al
and the high rates found in EUFEST by Kahn et al. Second, to
gain a better insight in the risks for developing DRMDs, we per-
formed an explorative analysis of awide range of potential clinical
correlates for DRMDs.
METHODS
Subjects
The GROUP study is a multicenter cohort study performed
in the Netherlands and Belgium. The objective of the GROUP
study was to investigate how the variation in expression and
course of nonaffective psychotic disorders relates to genetic and
nongenetic factors in patients, their family members, and unre-
lated controls. Clinicians working in the participating academic
centers and nearby psychosis departments identified eligible in-
and outpatients being treated a nonaffective psychotic disorder and
asked them for their informed consent. The full cohort consisted
of 1120 patients with nonaffective psychotic disorders, their fam-
ily members (1057 siblings and 919 parents), and 590 unrelated
controls.11 Korver et al10 described the details of the GROUP
project extensively.
Among the GROUP study's cohort, this study investigated
patients (i) with a Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV) diagnoses of schizophrenia
and related disorders (DSM-IV 295.x) or other psychotic disorders
(DSM-IV 297.x/298.x),11 (ii) on antipsychotic treatment, and (iii)
who completed a DRMD assessment at baseline or follow-up.
Measures
The GROUP study is a prospective and naturalistic study of
patients' clinical outcomes; these outcomes were assessed at base-
line and at 3-year follow-up. The 3-year interval is a compromise
between the need of a long follow-up to investigate outcome of
psychosis and the need of shorter intervals to detect fluctuations
in clinical outcomes. To prevent fatigue, assessments were recorded
in 2 separate 2-hour sessions within a week from each other. Be-
cause of the large size of the cohort, many raters were recruited.
All raters followed a 3-day workshop and bimonthly follow-up
training sessions. Assessments included general demographics such
as age and sex and clinical outcomes related to DRMDs and psy-
chosis. Psychotic disorders were diagnosed with the Comprehen-
sive Assessment of Symptoms and History12 and the Schedules
for Clinical Assessment for Neuropsychiatry 2.1.13 Psychopathol-
ogy was assessed with the Positive and Negative Symptom Scale
(PANSS).14 The IQ was assessed with the third edition of the
Wechsler Adult Intelligence Scale (WAIS-III).15 These scales
were administered at baseline and at follow-up in addition to
the DRMD scales listed below. The patients' current prescrip-
tion of antipsychotic medication(s) was registered at baseline
and follow-up interviews, that is, type (FGA/SGA/both), method
of administration (oral/depot), and dose. Because patients were
prescribed different antipsychotics, their doses could not be com-
pared directly. Daily defined doses (DDDs) describe the equiva-
lent doses of many antipsychotics; these equivalents are assigned
and reviewed by researchers of the World Health Organization.
Thus, converting the dose(s) of each patient's prescribed antipsy-
chotic(s) to his or her total DDDs allowed us to investigate the
overall effect of antipsychotic dose on DRMDs. Prescription of
anticholinergic medication(s) was also registered.
Parkinsonism (Rest Tremor, Rigidity,
and Bradykinesia)
Parkinsonism was assessed with the Unified Parkinson’s
Disease Rating Scale (UPDRS) Part III.16 This scale consists of
27 items (range, 0–4) and covers the 3 subdomains of parkinson-
ism: rest tremor (5 items), rigidity (5 items), and bradykinesia (9
items). Clinical parkinsonism was defined as at least (i) a “mild”
score on the tremor or rigidity items, (ii) a “moderate” score on
the other items, or (iii) a “mild” score on 2 or more of the other
items.4 Clinical rest tremor, rigidity, and bradykinesia were, re-
spectively, defined as scoring a mild score or more on the rest
tremor items, at least a mild score on the rigidity items, and at least
a moderate score or 2 mild scores on the bradykinesia items.
Akathisia
Akathisia was assessed with the Barnes Akathisia Rating Scale
(BARS).17 Clinical akathisia was defined as at least a mild score
on the “global clinical assessment” item17 (range, 0–5).
Tardive Dyskinesia
Tardive dyskinesia was assessed with the first 7 items of
the Abnormal Involuntary Movement Scale (AIMS)18 (range,
0–4). Clinical tardive dyskinesia was defined with the Schooler
and Kane criteria, that is, at least a moderate score or at least 2
mild scores.7
Tardive Dystonia
Severity of tardive dystonia was assessed with a single item
(range, 0–4) added to the BARS.10 Clinical tardive dystonia was
defined as a mild score or higher.19
Statistical Analysis
STATA (version 12.1, StataCorp) was used for the statistical
analyses. Release number 4.00 of the GROUP data set was inves-
tigated. Missing AIMS, UPDRS, and PANSS items were replaced
by mean scores of the nonmissing items when at most 1, 3, and 4
items were missing, respectively. We opted for this approach over
multiple imputation because most of the scores on the DRMD scale
items were zero, and we found that multiple imputation was
too conservative even in patients with non-zero scores on the
other items.
Prevalence, Incidence, and Persistence
Drug-related movement disorder prevalence, incidence, and
persistence rates were determined and the individual rates for par-
kinsonism (bradykinesia, rigidity, and tremor), akathisia, tardive
dyskinesia, and tardive dystonia. Prevalence rates were deter-
mined at baseline and at follow-up, and incidence rates were deter-
mined over this 3-year period. Persistence rates were defined as
the percentage of patients that have a DRMD at baseline and
follow-up of the total patients with a DRMD at baseline that were
assessed at baseline and at follow-up.
Clinical Correlates
Multivariate regression models were used to identify poten-
tial correlates of DRMDs at baseline and at follow-up. Because
ranges of scores on the UPDRS, BARS, and AIMS scales and
the dystonia item vary, they were rescaled to a possible range of
0 to 100 to improve their comparability (eg,C = A/B 100, where
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C is the rescaled score, A is the observed score, and B is the max-
imum range of the score). These 4 rescaled scores were regressed
on a 4-level factor that distinguishes the 4 DRMD outcomes and a
number of additional covariates/predictors, detailed below, and
their interactions with the 4-level factor. Because the 4 DRMD
scores were clustered within patients, we allowed residuals within
patients to be correlated using an unstructured covariance matrix,
also allowing residual variances to differ across the 4 outcomes.
Using a multivariate model to analyze all 4 outcomes simulta-
neously allowed us to increase the power of the analysis by keep-
ing the effect of several covariates constant over each DRMD
outcome. In addition, we obtained information on the correlation
between the DRMDs themselves (after accounting for the influ-
ence of any predictors in the model). The covariates set to interact
with the 4-level factor (allowing the model to determine their re-
spective associations with each individual DRMD) were age,3,20
ethnicity (Caucasian/other),21 prescribed antipsychotic dosage
(DDD),22–24 PANSS score negative items,3,6 PANSS score posi-
tive items,3,20 and WAIS-III scale IQ score.25 The covariates and
a priori confounders in the model set to have a constant effect over
the DRMDs were sex22,25 and the number of prescribed antipsy-
chotics,22 their type(s) (FGA/SGA/both),3 and method of admin-
istration (oral/depot).3,22 The other covariates in the model were
incidence and persistence rates, which were not compared among
FGAs and SGAs because of the naturalistic design of the GROUP
study and considering the 3-year interval between assessments.
RESULTS
Sociodemographic and clinical characteristics of the patients
who met the inclusion criteria are summarized in Table 1. Of the
1120 patients in the GROUP cohort, 828 patients completed at
least 1 DRMD assessment and were eligible for inclusion in the
prevalence, incidence, and persistence analyses. At the follow-up
assessment, 447 patientswere eligible for analysis. The primary rea-
son for the high attrition rate was patients lost to follow-up. A test
of proportion showed that the patients who were lost to follow-up
after the baseline assessment had significantly more DRMDs
(z = −3.4, P < 0.01). Most patients were around the age of 30;
96 (12%) patients were younger than 20 years, 473 (57%) patients
were between 20 and 30 years, 199 (24%) patients were between
30 and 40 years, and 52 (6%) patients were older than 40 years.
Table 2 lists the prevalence, 3-year incidence and persistence rates
of DRMDs, and most frequent combinations thereof. The preva-
lence and incidence rates were highest for parkinsonism followed
by akathisia, and the most prevalent combination of DRMDs was
having both parkinsonism and akathisia. Table 2 also lists the
DRMDs persistence rates. Parkinsonism (especially bradykinesia)
was the most persistent DRMD. A test of proportion showed that
akathisia was significantly more prevalent in FGAs than SGAs at
baseline (22.4%/9.9%,P < 0.01); therewere trends toward akathisia
beingmore prevalent in FGAs at follow-up (13.5%/5.9%, P = 0.08)
and parkinsonism being more prevalent in FGAs at baseline
(39.7%/29.8%, P = 0.08). The prevalence of the other DRMDs
did not differ significantly between patients treated with FGAs
and SGAs.We also investigated the difference between the 2 most
frequently prescribed SGAs olanzapine (26%/20% of patients at
baseline/follow-up) and risperidone (20%/13% of patients at
baseline/follow-up). There were no significant differences in the
prevalence of DRMDs between patients treated with olanzapine
or risperidone. Only a trend toward baseline akathisia being more
prevalent in the patients treated with risperidone was observed
(13.1%/7.5%, P = 0.07).
Table 3 presents an overviewof the clinical correlates at base-
line and follow-up. Patients with a combined antipsychotic World
Health Organization defined daily dose equivalent greater than
five (n = 28) affected the mixed-effects model substantially and
were excluded from the analysis, as their antipsychotic dose values
were presumably incorrectly registered during their baseline and/
or follow-up interviews. A total of 630 patients completed all re-
quired assessments for the regression analyses at baseline and were
investigated in the model, and 301 patients were investigated in
the model of the follow-up data. The association between negative
psychopathology symptoms (PANSS negative score) and parkin-
sonism (UPDRS score) was the only association significant at both
baseline and follow-up, with patients scoring on average 0.41 [95%
confidence interval (CI), 0.31–0.51] and 0.35 (95% CI, 0.18–0.52)
points higher on the UPDRS for each 1-point increase on the PANSS
negative scale. There was also a significant association between
cognitive functioning (WAIS-III IQ scores) and parkinsonism:
TABLE 1. Sociodemographic and Clinical Characteristics at Baseline of Patients Having Completed aMovement Disorder Assessment
n Mean (SD) Range %
Age, y 828 27 (7) 15–57
Sex (% male) 828 79
Ethnicity Caucasian 828 78
Other 22
DSM-IV classification Schizophrenia and related disorders 828 88
Other nonaffective psychotic disorders 12
Illness duration, y 828 4 (4) 0–41
IQ (WAIS-III) 794 94 (15) 57–140
PANSS General (range, 16–112) 808 28 (8) 16–65
Positive (range, 7–49) 808 13 (5) 7–37
Negative (range, 7–49) 803 14 (6) 7–38
Antipsychotic Dose (DDD) 670 1.1 (0.7) 0.1–4.5
Generation FGA 698 11
SGA 87
Both 2
Depot (% prescribed) 698 6
% concomitant prescriptions of anticholinergic medication(s) 828 6
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UPDRS scores were on average 0.66 (95% CI, 0.31–1.02) and
0.70 (95% CI, −0.14 to 1.26) points lower for every 10 additional
IQ points. However, this association was only significant at
baseline. Table 4 reports the strengths of the correlations between
the DRMDs at baseline and follow-up. Significant correlations
were found between parkinsonism and akathisia, parkinsonism
TABLE 2. Prevalence and Incidence of DRMDs and Combinations Thereof of All Patients and Patients On and Off Antipsychotic
Treatment
Prevalence
Baseline Follow-Up Incidence Persistence*
n % n % n % n %
DRMDs 828 39.3 447 36.5 249 24.5 148 54.7
Parkinsonism 813 31.9 440 31.4 268 21.3 117 53.0
Tremor 813 9.0 440 10.7 349 9.5 36 22.2
Rigidity 813 6.3 440 5.2 366 4.6 19 10.5
Bradykinesia 813 13.4 440 16.8 342 14.0 43 44.2
Akathisia 820 11.0 446 7.2 356 5.1 35 17.1
Tardive dyskinesia 821 3.7 446 3.6 383 3.1 10 20.0
Tardive dystonia 813 1.5 447 1.8 384 1.6
Parkinsonism and akathisia 806 5.5 439 3.0 242 1.2 13 7.7
Parkinsonism and tardive dyskinesia 806 1.7 439 2.3 260 1.9
This table only reports the combinations of DRMDs that are relatively prevalent (>1.0%).
*Persistencewas defined as the percentage of patients with a DRMD at both baseline and follow-up of all patients with a DRMD at baselinewhom com-
pleted the follow-up assessment; this was only determined when at least 10 patients with a DRMD at baseline completed the follow-up assessment.
TABLE 3. Multivariate Model Results: Regression Coefficients of the Correlates for Parkinsonism, Akathisia, Tardive Dyskinesia, and
Tardive Dystonia Scores at Baseline (n = 630) and Follow-Up (n = 301)
DIMD, Scale
(Total Range)
Range in
Sample
Parkinsonism,
UPDRS (0–108)
Akathisia,
BARS (0–5)
Tardive Dyskinesia,
AIMS (0–28)
Tardive Dystonia,
Dystonia Item (0–4)
β (95% CI) P β (95% CI) P β (95% CI) P β (95% CI) P
Baseline:
Age, y 15–57 .12 (.04 to .19) 0.002 −.00 (−.01 to .00) 0.308 .00 (−.01 to 0.2) 0.773 .00 (−.00 to .01) 0.311
Ethnicity (not Caucasian) −.38 (−1.65 to .89) 0.559 .00 (.15 to .15) 0.987 −.14 (−.39 to .10) 0.258 0.00 (−.07 to .07) 0.943
Antipsychotic dose
(DDD)
0.1–4.5 .07 (−.73 to .87) 0.865 −.04 (−.13 to .05) 0.422 .10 (−.06 to .26) 0.225 −.01 (−.05 to .04) 0.801
Positive symptoms
(PANSS)
7–37 −.06 (−.17 to .04) 0.244 .02 (.00 to .03) 0.011 −.02 (−.04 to .00) 0.100 .00 (−.00 to .01) 0.189
Negative symptoms
(PANSS)
7–38 .41 (.31 to .51) 0.000 .01 (−.00 to .02) 0.246 .03 (.01 to .05) 0.002 .00 (−.00 to .01) 0.416
IQ (WAIS-III)* 57–146 −.66 (−1.02 to −.31) 0.000 −.03 (−.07 to .01) 0.180 −.01 (−.08 to .06) 0.789 −.02 (−.04 to .00) 0.064
Follow-up:
Age (years) 18–56 .09 (−.04 to .21) 0.167 .00 (−.01 to .01) 0.694 −.00 (−.03 to .02) 0.797 −.00 (−.01 to .1) 0.775
Ethnicity (not Caucasian) −.24 (−2.24 to 1.77) 0.818 −.00 (−.18 to .17) 0.956 .12 (−.25 to .50) 0.526 .04 (−.08 to .15) 0.518
Antipsychotic dose
(DDD)
0.0–5.0 −.08 (−1.09 to 0.93) 0.877 .02 (−.06 to .10) 0.665 .15 (−.05 to .34) 0.137 .07 (.02 to .12) 0.012
Positive symptoms
(PANSS)
7–29 .14 (−.06 to .33) 0.170 .03 (.01 to .04) 0.002 .04 (.01 to .08) 0.015 .01 (−.00 to .02) 0.138
Negative symptoms
(PANSS)
7–39 .35 (.18 to .52) 0.000 .00 (−.01 to .02) 0.844 .00 (−.03 to .04) 0.836 −.00 (−.01 to .01) 0.478
IQ (WAIS-III)* 65–146 −.70 (−1.26 to −.14) 0.014 .01 (−.04 to .06) 0.741 −.04 (−.15 to .06) 0.412 −.00 (−.03 to .03) 0.970
The β coefficients and CIs in this table represent changes on the respective DRMD scales (ie, on average a 10-year older patient scores 1.2 point higher
on the UPDRS assuming the patients' other independent variables are comparable). The reported independent variables were corrected for the a priori con-
founders sex and the number of prescribed antipsychotics, their generation (FGA/SGA/both), and method of administration (oral/depot). We found that pre-
scribing multiple antipsychotics significantly increased the severity of DRMDs (P = 0.003); this was found only at the follow-up assessment. Coefficients in
bold are considered significant (P < 0.010).
*Average difference in DRMD score per 10 IQ points.
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and tardive dyskinesia, and akathisia and tardive dyskinesia. These
correlations remained significant after correcting for the confound-
ing variables in the regression models.
DISCUSSION
This study shows that the prevalence and incidence rates of
DRMDs can be high even in a relatively young population pre-
dominately treated with SGAs. This stands in contrast with the
idea that SGAs are associated with low DRMD incidence and
prevalence rates. At baseline and follow-up, the DRMD preva-
lence rates of the GROUP cohort were 39.3% and 36.5%, respec-
tively, and the incidence rate was 24.5%. Parkinsonism was the
most common DRMD with an incidence rate of 21.3% and prev-
alence rates of 31.9% and 31.4% at baseline and follow-up. Par-
kinsonism was also the most persistent DRMD, persisting over
baseline and follow-up in 53.0% of the patients.
Prevalence Rates
The baseline prevalence rates of DRMDs in the GROUP co-
hort were remarkably high (39.3%). This could be of substantial
clinical impact as DRMDs are known to cause discomfort in af-
fected individuals1 and may affect functioning in daily life and
contribute to noncompliance of antipsychotic treatment.2 The
3-year follow-up data also show high prevalence rates of DRMDs
(36.5%). With a test of proportions, we found that only the preva-
lence of akathisia is slightly but significantly lower at the 3-year
follow-up. This study's DRMD prevalence rates are in line with
the reports of the EUFEST study, which investigated patients with
similar characteristics.8,9 However, this study did report a lower
prevalence rate for parkinsonism (11%) compared with our find-
ings (31%–32%). This discrepancy could be caused by the recruit-
ment of antipsychotic-naive patients in their baseline sample and
the higher prescription rate of anticholinergic medication in their
study. Another recent study reported even lower prevalence rates
for parkinsonism (2%) and akathisia (1%) in a population 7 years
younger.5 This is unexpected as the poor prognosis of individuals
with an early onset of schizophrenia26 might also suggest an in-
creased risk for DRMDs. Nevertheless, these authors did find high
prevalence rates of subclinical parkinsonism (26%) and akathisia
(12%).5 It could be that the rating scale they used (Simpson Angus
Scale) is less sensitive for detecting parkinsonism than the rating
scale (UPDRS) used in our study.27 However, this alone cannot ac-
count for the difference in prevalence of parkinsonism with our
study. In summary, our findings show that DRMDs prevalence rates
are high even in relatively young patients with relatively brief expo-
sure to predominately SGA treatment.
Incidence
One in 4 patients without a DRMD at baseline had a DRMD
at 3-year follow-up, and together with the high prevalence of
DRMDs at baseline, this finding indicates that most of the patients
in the GROUP study have had a DRMD at some point in time. Be-
sides being the most prevalent DRMD, parkinsonism also had the
highest incidence. A few other studies reported similar DRMD in-
cidence rates for parkinsonism (22%), akathisia (4%), and extra-
pyramidal symptoms (15%–30%).3,23,28–30 However, these studies
investigated populations with an increased risk of DRMDs (espe-
cially parkinsonism) as their patients were considerably older on
average23 and predominately treated with FGAs.3,25 We therefore
expected our sample to have lower DRMD incidence rates but
found that DRMDs incident rates in relatively young patients
are remarkably high.
The low incidence of tardive DRMDs in this study was in line
with our expectations, as the risk of developing a tardive DRMD in-
creases with the cumulative exposure to antipsychotics.31 The cu-
mulative exposure to antipsychotics was modest in the sample we
studied. The clinical implications of developing a tardive DRMD
can be substantial, as significant associations between tardive dys-
kinesia, dopamine supersensitivity psychosis, and treatment-
resistant schizophrenia have been reported.32 A meta-analysis of
11 studies comparing incidence rates of tardive dyskinesia re-
ported a mean annual incidence of 2.1%,28 which is similar to
our study (3.1%). The incidence of tardive dystonia was in line
with previous reports (0%–0.7%).23,30 Overall, the high incidence
rates we found indicate that DRMDs are a considerable problem
that most patients are likely to experience during the first years
of their antipsychotic treatment.
TABLE 4. Baseline and Follow-Up Pearson Correlation Coefficients Between DRMDs and the Respective Correlation Coefficients
Adjusted for the Independent Variables in the Regression Model
Parkinsonism Akathisia Tardive Dyskinesia
Pearson Adjusted Pearson Adjusted Pearson Adjusted
Parkinsonism (UPDRS)
Baseline
Follow-up
Akathisia (BARS)
Baseline 0.22 0.19
Follow-up 0.12 0.07
Tardive dyskinesia (AIMS)
Baseline 0.18 0.14 0.11 0.10
Follow-up 0.31 0.27 0.20 0.18
Tardive dystonia
Baseline 0.07 0.03 0.03 0.00 0.02 0.03
Follow-up 0.04 0.02 0.12 0.12 0.11 0.07
The Pearson correlation coefficients were determined for the same patients that were included in the regression models. Significant correlations are
marked in bold (P < 0.01).
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Persistence
In this study, persistence was defined as having a DRMD at
baseline and at follow-up. Persistence is a measure to determine
the extent of the burden caused by DRMDs. This study shows that
more than half of the patients with parkinsonism at baseline also
suffered from parkinsonism at follow-up. Few other studies re-
ported persistence rates. When reported, persistence rates of extra-
pyramidal symptoms (81%),29 parkinsonism (56%),33 akathisia
(5%–67%),33 and tardive dyskinesia (28%–80%)29,33 vary sub-
stantially. These studies differ from the current study as they inves-
tigated older patients on long-term antipsychotic treatment and
assessed DRMDs more frequently and on shorter intervals.29,33
Therefore, it was expected that this study's persistence rates would
be lower, as the chance of a DRMD persisting over this study's
3-year follow-up period is lower in comparison to the other stud-
ies' shorter measurement intervals. Although the persistence rates
for parkinsonism (53%), akathisia (17%), and tardive dyskinesia
(20%) determined in our study are slightly lower than the previ-
ously reported rates, they are still quite high when taken into ac-
count that our study sample is significantly younger and was
predominately treated with SGAs for a relatively brief period.
Drug-Related Movement Disorder Correlates
The large sample and wide range of outcomes investigated in
this study offered us the opportunity to investigate the associations
between DRMDs and potential correlates. The strongest associa-
tions that were found in this study were the interrelationships be-
tween DRMDs. Parkinsonism and tardive dyskinesia, and akathisia
and tardive dyskinesia were significantly correlated at baseline
and follow-up even when we adjusted for the effects of con-
founders. At baseline there was also a significant correlation be-
tween parkinsonism and akathisia. Previous studies have also
reported that extrapyramidal symptoms3,21 (akathisia and parkin-
sonism20) and tardive dyskinesia are interrelated. Our model also
confirms that parkinsonism is significantly associated with age,
IQ, and negative symptoms.3,6,25 However, the association that
we found between age and severity of parkinsonism was relatively
weak. On average, a 10-year older patient only scored 1.2 more
points on the UPDRS. As the association between parkinsonism
and age is much stronger in older populations,3,23 we believe the
risk for parkinsonism increases nonlinearly with age. Interestingly,
we found that parkinsonism, IQ, and negative symptomswere sig-
nificantly associated with each other and seem to be interrelated.
Several other studies have also reported significant correlations
between parkinsonism and cognitive deficits,6,25 parkinsonism and
negative symptoms,6 and cognitive deficits and negative symp-
toms.34 The interrelationship between motor, cognitive, and nega-
tive symptoms supports the theory that these symptoms are
integral symptoms of schizophrenia and other psychotic disor-
ders, as proposed in the neurodevelopmental hypothesis.35 This
hypothesis is further supported by studies that have shown that
cognitive, motor, and social impairment are common in individ-
uals destined to develop schizophrenia,35 and other studies reporting
that functional outcome and response to treatment are associated
with increased severity of cognitive,36 motor,37 and negative
symptoms.38 Therefore, regularly assessing DRMDs can improve
the accuracy of the diagnosis, which may result in a better progno-
sis of schizophrenia. Nevertheless, akathisia and tardive dyskine-
sia20 were only weakly associated with psychopathology in this
study, and they were not associated with IQ. This suggests that,
in contrast to parkinsonism, akathisia and tardive dyskinesia are
not interrelated with cognitive functioning and psychopathology,
and the conflicting reports by other studies support this.20,24,39
Several studies have reported an association between antipsychotic
treatment and severity of DRMDs.3,20,23 We did not find any sig-
nificant associations between severity of DRMDs and antipsy-
chotic treatment with our model. An explanation could be that
relevant changes in antipsychotic treatment in response to DRMDs
were not recorded by this study. As this study used a naturalistic
design and we only recorded the current antipsychotic treatment
at baseline and at 3-year follow-up, changes in antipsychotic treat-
ments before baseline or between baseline and follow-up were not
recorded. However, when confounders were not controlled for,
opposed to the regression models, we did find that akathisia was
significantly more prevalent in patients treated with FGAs than
SGAs. In addition, akathisia was almost significantly more prev-
alent in the patients treated with risperidone as opposed to the pa-
tients treated with olanzapine. The low prevalence of akathisia in
patients treated with olanzapine is in accordance with a previous
study.8 Findings of previous studies on the relation between sex
and DRMDs are conflicting.3–5,21,23 Our model did not find an as-
sociation between sex and DRMDs; therefore, we think it is un-
likely that the association between sex and DRMDs is strong.
Overall, these associations underline the diagnostic and prognos-
tic value of DRMDs, which may have been overlooked, especially
considering that tardive dyskinesia has been associated with dopa-
mine supersensitivity psychosis and treatment-resistant schizo-
phrenia32 and that subtle spontaneous DRMDs are present in
individuals at ultrahigh risk for psychosis40 and family members
of patients with schizophrenia.19
Strengths and Limitations
This is one of few studies to investigate DRMDs in a large
sample of relatively young patients a few years after onset of psy-
chosis. It enabled us to assess DRMDswith minimal confounding
by extended and diverse prior antipsychotic and other treatments.
Furthermore, the large size of the investigated cohort and the use
of specific (valid and reliable) rating scales for each DRMD and
the fact that we assessed not only prevalence but also incidence
and persistence of DRMDs are the most important strengths of
this study. These aspects greatly benefit the generalizability of
our findings. IN addition, they provided us with enough statistical
power to investigate the associations of DRMDswith awide range
of clinical and sociodemographical factors.
It is likely that the incidence, persistence rates, and the prev-
alence rates at follow-up were even higher than the figures we re-
ported, as the DRMD baseline prevalence rates for the group of
patients that were lost to follow-up after the baseline assessment
were significantly higher than those of the patients that also com-
pleted the follow-up assessment.
A limitation of this study was that the time window between
baseline and follow-up (3 years) may have been too broad to de-
tect all relevant fluctuations of DRMDs, antipsychotic treatment,
and psychopathology. Considering that the incidence and persis-
tence rates were determined by data from these 2 time points,
and not by cumulative data, we think that the rates we found may
even have been an underestimation. Furthermore, the naturalistic
design of this study may have also limited the possibility to inves-
tigate associations between treatment and DRMDs, as treatment
may have been altered because of DRMDs.
CONCLUSIONS AND CLINICAL IMPLICATIONS
This study shows that DRMDs occur frequently in relatively
young patients predominately on SGA treatment. The high inci-
dence and persistence rates result in many patients having DRMDs
merely a couple of years after developing psychosis. This is con-
cerning as DRMDs have a substantial negative impact on the
quality of life of these patients. This underscores the importance
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of accurate monitoring of DRMDs even in the early years of treat-
ment of psychotic syndromes. Furthermore, to some extent, DRMDs
may be of prognostic and diagnostic value for schizophrenia and
other psychotic disorders, as they have been related to psychopa-
thology and cognitive functioning, which has been confirmed by
our findings. Furthermore, they also share a similar underlying
neuropathology, and movement disorders occur in antipsychotic-
naive patients as well. Therefore, we recommend future studies
to explore the use of movement disorders for the diagnosis and
prognosis of psychotic disorders.
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